Mounjaro (tirzepatide) Update

Practices can prescribe GLP-1 medication to patients who meet the criteria. This is those with a body mass index (BMI) of 40 kg/m² or more (or 37.5 kg/m² for people from minority ethnic family backgrounds) who are at least 18 years old and have at least four of the following long-term conditions:

Atherosclerotic cardiovascular disease (ASCVD)
Hypertension
Dyslipidaemia
Obstructive sleep apnoea
Type two diabetes mellitus

From 23 June 2026, the required BMI will reduce to 35, or 32.5 for those from a minority ethnic family background.

Anyone prescribed with GLP-1 medication must also be referred to, and engage with, the Healthier You: Behavioural Support for Obesity Prescribing (BSOP) Programme.

Patients identified as eligible will be contacted by the practice.

Page last reviewed: 14 May 2026
Page created: 17 June 2025